miR-122 exosomes from fat stem cells sensitize HCC models to chemo
Adipose MSC exosomes loaded with miR-122 delivered the microRNA into HepG2 cells, downregulated CCNG1/ADAM10/IGF1R, and increased chemosensitivity in vitro and in xenografts combined with agents such as sorafenib.
Source
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma
Study at a glance
- Design
- Animal / in-vitro — miR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy
- N
- In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text
- Population
- HepG2 hepatocellular carcinoma cells and nude-mouse xenografts
- Outcome
- Chemosensitivity and xenograft tumour response with miR-122 exosomes
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Authors transfected adipose tissue–derived MSCs (AMSCs) to express miR-122, harvested exosomes (122-Exo), treated HepG2 HCC cells, and tested chemosensitivity plus HepG2 xenograft responses with regimens including sorafenib (5 mg/kg).
What they found
AMSCs packaged plasmid-expressed miR-122 into exosomes (~40-fold higher miR-122 in producer cells). 122-Exo raised miR-122 in HepG2 cells vs control exosomes, reduced CCNG1/ADAM10/IGF1R, and increased chemosensitivity via apoptosis and cell-cycle arrest. In xenografts, benefit depended on combining miR-122 transfer with chemotherapy; exosomes alone did not significantly shrink tumours vs vehicle in the reported comparison.
The limits
What it doesn't show
This is a preclinical HepG2/xenograft strategy, not a completed human HCC trial. Exosomes alone without chemo did not show significant tumour-volume benefit vs vehicle in the cited comparison. Delivery, dosing, and safety in patients remain open.
Key terms
- miR-122
- Liver-enriched microRNA packaged into AMSC exosomes to sensitize HCC cells.
- AMSC exosomes
- Extracellular vesicles from adipose mesenchymal stem cells used as delivery vehicles.
- 122-Exo
- Exosomes from miR-122–transfected AMSCs.
- CCNG1 / ADAM10 / IGF1R
- miR-122 target genes linked to drug resistance/sensitivity that fell after 122-Exo treatment.
- Chemosensitivity
- Increased cell death/cell-cycle arrest response to chemotherapeutic agents after miR-122 delivery.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
What does 122-Exo deliver?
Common questions
What vehicle delivered miR-122?
Exosomes from adipose tissue–derived MSCs engineered to express miR-122.
Did AMSCs package miR-122 into exosomes?
Yes — miR-122 was ~40-fold higher in transfected AMSCs, and exosomes carried the miRNA.
Which target genes fell in HepG2 cells?
CCNG1, ADAM10, and IGF1R among others.
Did exosomes alone shrink xenografts vs vehicle?
Authors report no statistically significant tumour volume/weight difference for exosome-only vs vehicle in that comparison — benefit was framed with chemotherapy combinations.
Is this ready for routine HCC care?
No — it is a preclinical treatment-strategy paper, not a finished patient RCT.
More on Oncology outcomes